Literature DB >> 1798679

14C-isomazole disposition in man after oral administration.

J R Woodworth1, A F DeLong, A F Fasola, S Oldham.   

Abstract

A 50-mg dose containing 50 microCi 14C-isomazole was administered orally to five healthy male volunteers. Blood, plasma, urine, feces, and saliva were collected and measured for total 14C; in addition, all collections except feces were measured for parent drug (ISO) and three metabolites: hydroxyisomazole (OHISO) and sulfone (SULF) and hydroxysulfone (OHSULF) analogues. Urine and fecal recoveries accounted for 97.0% of the drug administered, with 62.6% excreted in urine and 32.4% in feces. Only 47% of the drug recovered in urine could be identified, with ISO the largest constituent. Total plasma 14C peaked at 1.5 hr, indicating rapid absorption, and produced a mean half-life of 3.7 hr. This was similar to the total 14C half-life found in blood (3.1 hr) but longer than in red blood cells (1.8 hr) or saliva (1.4 hr), suggesting that different ISO-related compounds contributed to the results found in each fluid or tissue. An unidentified metabolite(s) composed a large portion of circulating plasma 14C and produced the longer half-life encountered in plasma. ISO exhibited a short half-life (1.35 hr), a high oral clearance (Cls/F; 24.2 ml/min/kg), and some extravascular distribution (V beta; 3.07 L/kg). Total 14C in red blood cells and saliva related very well to plasma ISO disposition, suggesting preferential distribution of parent drug across cellular membranes. The estimated RBC:plasma ISO ratio (1.79) confirmed this hypothesis. Saliva may be used as a noninvasive means to monitor ISO disposition.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1798679     DOI: 10.1023/a:1015857324838

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

Review 1.  Combined vasodilator and inotropic therapy of heart failure: experimental and clinical concepts.

Authors:  R R Miller; A R Palomo; T A Brandon; C J Hartley; M A Quinones
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

2.  Acute, subchronic, and chronic toxicity of the cardiotonic isomazole in rats.

Authors:  G E Sandusky; R B Franklin; J R Means
Journal:  Fundam Appl Toxicol       Date:  1989-10

3.  Toxicological evaluation of the cardiotonic isomazole in the dog.

Authors:  J R Means; R B Franklin; G E Sandusky
Journal:  Fundam Appl Toxicol       Date:  1989-10

4.  Roles for Ca++ and cyclic AMP in mediating the cardiotonic actions of isomazole (LY175326).

Authors:  J S Hayes; N Bowling; G D Pollock; D W Robertson
Journal:  J Pharmacol Exp Ther       Date:  1986-04       Impact factor: 4.030

5.  Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.

Authors:  J N Cohn; D G Archibald; S Ziesche; J A Franciosa; W E Harston; F E Tristani; W B Dunkman; W Jacobs; G S Francis; K H Flohr
Journal:  N Engl J Med       Date:  1986-06-12       Impact factor: 91.245

6.  Isomazole disposition in man as a function of dose and route of administration.

Authors:  J R Woodworth; A F Delong; A F Fasola; S Oldham
Journal:  Biopharm Drug Dispos       Date:  1991-12       Impact factor: 1.627

7.  Pharmacology of LY175326: a potent cardiotonic agent with vasodilator activities.

Authors:  J S Hayes; G D Pollock; H Wilson; N Bowling; D W Robertson
Journal:  J Pharmacol Exp Ther       Date:  1985-05       Impact factor: 4.030

8.  A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1983-10       Impact factor: 24.094

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.